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Abstract
Background: Gene expression profiling has been used to define molecular phenotypes of complex diseases such as breast
cancer. The luminal A and basal-like subtypes have been repeatedly identified and validated as the two main subtypes out of a
total of five molecular subtypes of breast cancer. These two are associated with distinctly different gene expression patterns
and more importantly, a significant difference in clinical outcome. To further validate and more thoroughly characterize these
two subtypes at the molecular level in tumors at an early stage, we report a gene expression profiling study using three different
DNA microarray platforms.
Results: Expression data from 20 tumor biopsies of early stage breast carcinomas were generated on three different DNA
microarray platforms; Applied Biosystems Human Genome Survey Microarrays, Stanford cDNA Microarrays and Agilent's
Whole Human Genome Oligo Microarrays, and the resulting gene expression patterns were analyzed. Both unsupervised and
supervised analyses identified the different clinically relevant subtypes of breast tumours, and the results were consistent across
all three platforms. Gene classification and biological pathway analyses of the genes differentially expressed between the two
main subtypes revealed different molecular mechanisms descriptive of the two expression-based subtypes: Signature genes of
the luminal A subtype were over-represented by genes involved in fatty acid metabolism and steroid hormone-mediated
signaling pathways, in particular estrogen receptor signaling, while signature genes of the basal-like subtype were over-
represented by genes involved in cell proliferation and differentiation, p21-mediated pathway, and G1-S checkpoint of cell cycle-
signaling pathways. A minimal set of 54 genes that best discriminated the two subtypes was identified using the combined data
sets generated from the three different array platforms. These predictor genes were further verified by TaqMan® Gene
Expression assays.
Conclusion: We have identified and validated the two main previously defined clinically relevant subtypes, luminal A and basal-
like, in a small set of early stage breast carcinomas. Signature genes characterizing these two subtypes revealed that distinct
molecular mechanisms might have been pre-programmed at an early stage in different subtypes of the disease. Our results
provide further evidence that these breast tumor subtypes represent biologically distinct disease entities and may require
different therapeutic strategies. Finally, validated by multiple gene expression platforms, including quantitative PCR, the set of
54 predictor genes identified in this study may define potential prognostic molecular markers for breast cancer.
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Breast cancer is a complex disease and although recent
research has emphasized the heterogeneity of the disease,
much of its biology remains poorly understood. In partic-
ular, genomic tools such as DNA microarrays hold great
potential for the deciphering of the molecular patterns of
tumors and the identification of new and improved clini-
cal markers. Gene expression profiling has been used
extensively over the last few years to analyze breast tumors
and has resulted in several gene signatures associated with
different clinical parameters [1-7]. Using an unsupervised
approach, we have identified five clinically relevant sub-
types of breast tumors [4,8], which have been further val-
idated in independent data sets [3,9-14]. Of these, the two
main subtypes are associated with the most significant dif-
ference in clinical outcome: Patients with luminal A type
tumors are facing a relatively good prognosis, whereas
patients with basal-like tumors experience a much shorter
overall-and disease-free survival period [10]. They are also
associated with differences in pathologic response to
chemotherapy [9,10,15].
Our earlier findings suggested that the distinct expression
patterns of the tumor subtypes and the significant differ-
ences in disease outcome are likely to be caused, at least in
part, by alterations in specific cellular pathways and/or
different cell type origin. The luminal A type tumors are
characterized by high expression of the estrogen receptor
(ESR1) and a handful of other genes generally co-
expressed with ESR1, many of which are genes typically
expressed in the luminal epithelium that lines the ducts.
The basal-like tumors on the other hand, are characterized
by high expression of some basal epithelial markers such
as KRT5, KRT17 and LAMC2 (laminin), and many cell
cycle-regulated genes [16,17]. A more thorough character-
ization of the molecular basis underlying these subtypes,
in particular in breast carcinomas at an earlier stage, will
help us to better understand breast cancer diseases at cel-
lular levels and hopefully provide new molecular prog-
nostic markers and targets for therapy.
In this study, we profiled 20 samples from early breast car-
cinomas (T1/T2) using three different microarray plat-
forms to address the question of uniformity of the breast
cancer phenotypes with different technologies. We identi-
fied differentially expressed genes between the two main
tumor subtypes, luminal A and basal-like, and subjected
these to protein classification and pathway analyses.
Finally, we identified a minimum set of genes with the
best possible predictive power for an expression-based
prognostic assay for the two clinically relevant subtypes of
breast cancer.
Results
Identification and validation of tumor subtypes in early 
breast cancer
Our first approach for identifying the previously described
tumor subtypes was to correlate the expression patterns of
the 20 early stage breast carcinomas analyzed by Applied
Biosystems Expression Array System with the previously
published expression centroids of the five tumors sub-
types [10]. The correlation matrix summarized as a heat
map is shown in Figure 1A. The previously identified sub-
types were evident also in this small tumor set. Using a
correlation coefficient cutoff of 0.2, six tumors were
defined as basal-like, seven were luminal A, three tumors
were ERBB2+, one luminal B and finally, one was identi-
fied as normal breast-like. Two tumors remained unclassi-
fied using the 0.2 threshold.
Unsupervised hierarchical clustering of the 20 tumors
using the 526 mapped intrinsic genes identified three sub-
clusters of samples based on their expression patterns
(Figure 1B). Individual dendrogram branches are colored
according to the strongest correlation of the correspond-
ing tumor with a subtype centroid. Among these sub-
groups, the clearest distinction was observed between the
luminal A (ER+) and the basal-like (ER-) subtypes, as has
been repeatedly reported.
As a second approach to validate the tumor subtypes in
this data set, we applied a supervised analysis using "Near-
est Shrunken Centroid Classifier" and the PAM software.
We took the previously published 122 Norway/Stanford
data set [10] and the mapped 526 genes as the training set
to identify predictor genes for the five subtypes. With a
threshold (∆) of 1 and 10-fold cross validation, we built a
classifier containing 428 genes which gave < 5% misclas-
sification error (data not shown). We then used this clas-
sifier to predict the subtypes of the 20 tumors analyzed in
this study. The prediction results from the supervised
analysis were overall consistent with the unsupervised
analysis using hierarchical clustering and centroid correla-
tion analysis: 6 tumors were predicted to be basal-like, 8
tumors were predicted to be luminal A, 4 were determined
as ERBB2+, 1 as luminal B, and 1 was unclassifiable (Fig-
ure 2, top panel). In other words, all but one sample were
assigned to a subtype with high prediction probability;
however, it is worth to note that the prediction accuracy
may be over-estimated as the predictor genes are a subset
of those used to define the subtypes in the first place.
Confirmation of the luminal A and basal-like subtypes 
using different array platforms
We also analyzed the same 20 tumor samples on Stanford
Human cDNA microarrays and Agilent Whole Human
Genome Oligo Microarrays. Centroid correlation analysis
was performed as described above using the 510 commonPage 2 of 15
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Unsupervised approach to identify breast cancer subtypesFig r  1
Unsupervised approach to identify breast cancer subtypes. (A) Correlation of breast tumor samples with the previ-
ously identified five subtypes of breast tumors. 526 out of 552 previously identified "intrinsic" genes were cross-mapped to 
Applied Biosystems Human Genome Survey Microarray and used for centroid correlation analysis and hierarchical clustering. 
Correlations with the centroids of the five subtypes were calculated for each sample from this study (the two microarray rep-
licates for each sample were averaged). Samples were assigned to a subtype with which it showed the highest correlation using 
a cutoff value of 0.2. (B) Unsupervised hierarchical clustering of 20 breast tumor tissues analyzed by AB arrays using the 526 
mapped intrinsic genes (the two microarray replicates for each sample are shown). The level of expression of each gene in 
each sample, relative to the median level of expression of that gene across all the samples, is represented using a red-black-
green color scale as shown in the key (green: below median; black: equal to median; red: above median). (Left panel): Scaled 
down representation of the entire cluster of the 526 intrinsic genes and 20 tissue samples. (Right panel): Experimental dendro-
gram displaying the clustering of the tumors into three distinct subgroups. Branches are color-coded according to the subtype 
with which the corresponding tumor sample showed the highest correlation. Tumors with low correlation (< 0.2) with a spe-
cific subtype are indicated by gray branches.
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BMC Genomics 2006, 7:127 http://www.biomedcentral.com/1471-2164/7/127intrinsic genes mapped among all three platforms. Unsu-
pervised hierarchical clustering of the three data sets
revealed the exact same subgroups of tumors, with the
luminal A and the basal-like subtypes as the most pre-
dominant and distinct (Figure 3A). PAM analysis showed
consistent prediction of subtype for each tumor sample
from the three data sets except for two samples
(MicMa148 and MicMa 020; see Figure 2). Overall, there
was consistency in identifying these biological subtypes
between all three platforms.
Molecular characterization of luminal A and basal-like 
subtypes of breast tumors
To molecularly characterize these two subtypes, we first
identified the most differentially expressed genes as the
"signature" genes using data from the Applied Biosystems
Expression Arrays, as this system provides a comprehen-
sive coverage of the genome including genes not covered
by other commercial microarrays. ANOVA analysis cou-
pled with Benjamini and Hochberg False Discovery Rate
multiple testing corrections were performed on six lumi-
nal A samples and six basal-like tumor samples (to be
most stringent in this analysis, samples with centroid cor-
relation coefficient > 0.3 were used, therefore, MicMa088
and MicMa 132 were excluded, see Figure 1A). 1210 genes
represented by 1244 probes were identified as the "signa-
ture" genes meeting the following criteria: (1) Detectable
(signal to noise > 3) in > 50% samples; (2) > 2-fold
change between the two subtypes, and (3) False discovery
rate < 5% (see Additional file 1). Figure 4 displays a hier-
archical clustering diagram of the 12 tumor samples using
these 1210 signature genes. Among the signature genes,
613 probes (603 genes) were specifically over-expressed
in luminal A type tumors (luminal A "signature" genes),
which included some previously identified markers, such
as ESR1, GATA3 and LIV1 [10], as well as many other
potential marker genes for this subtype. One example is
the EMP2 gene, which encodes a tetra-span membrane
protein that has been reported to suppress B-cell lym-
phoma tumorigenicity [18]. In the basal-like tumors, 631
Prediction of tumor subtype by Prediction Analysis of Microarrays (PAM)Figure 2
Prediction of tumor subtype by Prediction Analysis of Microarrays (PAM). 428 genes were selected at a threshold of 
1.0 that separated the two subtypes with the lowest overall misclassification rate of 5% (data not shown). Predicted probabili-
ties of subtype for each tumor sample analyzed on Applied Biosystems Human Genome Survey Microarrays (top panel), Stan-
ford Human cDNA arrays (middle panel) and Agilent Whole Human Genome Microarrays (bottom panel) were computed 
using the predictive model built using these 428 predictor genes.Page 4 of 15
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Validation of the luminal A and basal-like subtypes using three microarray platformsFigure 3
Validation of the luminal A and basal-like subtypes using three microarray platforms. (A) Unsupervised hierarchi-
cal clustering of 20 breast tumor tissues analyzed by Applied Biosystems (two replicates per sample), Stanford cDNA and Agi-
lent arrays using the 510 mapped intrinsic genes. The data from each platform were first transformed independently and then 
combined for clustering: the level of expression of each gene in each sample (Applied Biosystems microarrays: normalized sig-
nal intensity; Stanford cDNA and Agilent microarrays: normalized log2 ratio of the sample vs. the reference (UHR)) was trans-
formed into a log2 ratio relative to the median level of expression of that gene across all the samples within the data set of the 
given platform. The experimental dendrogram displays the clustering of the tumors into distinct subgroups. Branches are 
color-coded according to the subtype with which the corresponding tumor sample showed the highest correlation. Tumors 
with low correlation (< 0.2) with a specific subtype are indicated by gray branches. Luminal A subtype (dark blue) and basal-like 
subtype (red). (B) Venn Diagram of the most differentially expressed genes identified by all three different array platforms; 319 
genes were identified as the common signature genes using ANOVA analysis and the following criteria: (1) > 2-fold change 
between the two subtypes, and (2) False discovery rate < 5%. (C) PCA analysis of luminal A and basal-like samples using a min-
imum set of 54 genes identified by PAM analysis. Data sets generated from three array platforms (48 arrays total, two repli-
cates per sample in the Applied Biosystems data set) on 6 luminal A and 6 basal-like tumor samples using the 319 common 
signature genes were used as training set for the PAM analysis.
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Two-dimensional cluster diagram of the 1210 signature genes characterizing the luminal A and basal-like subtypesFigure 4
Two-dimensional cluster diagram of the 1210 signature genes characterizing the luminal A and basal-like sub-
types. ANOVA analysis was performed on 6 luminal A samples and 6 basal-like samples, coupled with Benjamini and Hochberg 
False Discovery Rate multiple testing corrections. The two subtypes of breast tumors (two replicates per sample) were clus-
tered into distinct clusters with reversed gene expression patterns: highly expressed in luminal A (bottom, 613 probes repre-
senting 603 genes) and highly expressed in basal (top, 631 probes representing 607 genes). The color scheme of the heat map 
was described in legend to Figure 1B and is shown in the key. Branches in the dendrogram are color-coded according to the 
subtypes: blue, luminal A; red, basal-like.
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BMC Genomics 2006, 7:127 http://www.biomedcentral.com/1471-2164/7/127probes (607 genes) were specifically over-expressed
(basal-like "signature" genes), and these included markers
such as KRT17, the Lamin B receptor (LBR) and DSC2.
Two interesting genes specifically overexpressed in these
tumors were MRAS, a well known oncoprotein of the RAS
superfamily whose mutant forms may transform mam-
mary epithelial cells [19], and CDCA7, a direct target of
the MYC oncogene [20].
To depict more detailed molecular portraits of these two
subtypes, we analyzed which biological processes were
over-represented by these signature genes using the PAN-
THER™ Protein Classification System analysis. The most
significantly over-represented biological processes are
listed in Table 1 (upper panel). Not surprisingly, very dif-
ferent processes are underlined by the signature genes of
the two subtypes: For luminal A, the most over-repre-
sented biological processes (p < 0.001) include fatty acid
metabolism (e.g. PGDS, ACOX2, PTE2B, HMGCL, CROT,
IVD, DECR2, FLJ20920, SLC27A2, ELOVL5, and MCCC2)
and steroid hormone mediated signaling (e.g. CRABP2,
AR, MGC32124, ESR1), whereas for the basal-like sub-
type, the most over-enriched processes (p < 0.001, only
top five listed) include ones that involve many cancer
"hallmark" genes, such as the cell cycle, cell proliferation
and differentiation, protein phosphorylation, B-cell-and
antibody-mediated immunity.
In a similar fashion, we also analyzed which cellular path-
ways played critical roles for defining the two distinct sub-
types using Jubilant's PathArt™ database. Table 1 (lower
panel) shows the top five PathArt™ pathways over-repre-
sented (p < 0.01) by the genes characteristic for luminal A
and the basal-like subtypes, respectively. Again, quite dis-
tinct pathways were found to underlie the two subtypes of
breast tumors. As expected, the most over-represented
pathway activated in the luminal A subtype is the ER sig-
naling pathway (see Additional file 2A): 6 genes within
the ER signaling pathway were significantly up-regulated
in these tumors, including the estrogen receptor 1 (ESR1)
and the estrogen-induced gene trefoil factor 1 (TFF1). This
is consistent with the previous findings that the luminal A
type tumors over-express ESR1 and other estrogen-
responsive genes and therefore are responsive to adjuvant
hormonal treatment [10,21]. On the other hand, the bio-
logical pathways underlying the basal-like subtype are
well known cancer-associated pathways. For example, fif-
teen genes in the p21 (CDKN1A) pathway were coordi-
nately over-expressed in the basal-like tumors, many of
these, such as MCM3, MCM4, MCM7 and MAD2L1 play
Table 1: Annotation and biological pathway analysis.
Protein Classifications and Pathways Number of Overlapping Genes Random Overlapping p value
PANTHER™ Protein Classification System (p < 0.001)
Luminal A subtype
Fatty acid metabolism 11 1.22E-04
Steroid hormone-mediated signaling 5 8.09E-04
Basal-like subtype
Cell cycle 55 2.50E-13
Cell proliferation and differentiation 40 9.62E-08
Protein phosphorylation 34 2.31E-07
B-cell-and antibody-mediated immunity 17 2.63E-07
Cell cycle control 25 2.38E-06
Jubilant PathArt™ Pathways (p < 0.01)
Luminal A subtype
ER Signaling Pathway 6 2.80E-04
Retinoic Acid Signaling Pathway 4 4.46E-04
Nucleotide Excision Repair Pathway 4 1.92E-03
IL6 Signaling Pathway 6 4.73E-03
EGF Signaling Pathway 7 4.92E-03
Basal-like subtype
p21 Mediated Pathway 15 9.14E-13
G1-S Checkpoint Pathway 10 1.03E-08
FAS Mediated Pathway 3 7.49E-04
p53 Signaling Pathway 7 8.45E-04
Upper part: The most significant biological processes (PANTHER™ Protein Classification System) over-represented by the luminal A subtype and 
the basal-like subtype (p < 0.001, top 5 are shown); Lower part: The most significant cellular pathways (PathArt™) over-represented by the luminal 
A subtype and the basal-like subtype (p < 0.01).Page 7 of 15
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Additional file 2B). Among many genes in this pathway,
SKP2 was found over-expressed in basal-like tumors; it
encodes a protein involved in the degradation of another
cyclin-dependent kinase inhibitor p27 (CDKN1B) and
recently reported to be over-expressed in many tumor
types and to correlate with poor prognosis [22,23].
Our findings confirm the existence of the intrinsic tumor
subtypes in these early breast cancer specimens, as has
been reported by others [3,13] and indicate that the cellu-
lar processes revealed by gene expression profiling have
been programmed at earlier stages of tumorigenesis.
Identification of the best set of prognostic genes 
discriminating the luminal A and basal-like subtypes of 
breast tumors
In an effort to identify a minimal set of genes that best
characterize the two subtypes and can form the basis for a
prognostic gene profile, we performed ANOVA analysis
on the data sets generated on each of the three array plat-
forms using the 16,611 common genes (see Additional
file 3) and the same six luminal A and six basal-like tumor
samples. Differentially expressed genes between the two
subtypes were determined for each platform using the
same criteria: (1) > 2-fold change between the two sub-
types, and (2) False discovery rate < 5%. From these, 319
genes were identified as the common signature genes (Fig-
ure 3B). The combined data sets generated from the three
platforms using expression data from these 319 common
genes was then used as the training set to perform PAM
analysis for the identification of the minimal set of genes
to best discriminate luminal A and basal-like tumors. Ten-
fold cross validation and a threshold of ∆ = 1.9 identified
54 genes with a misclassification error of ~ 16.7%. The
genes are listed in Additional file 4. Principle Component
Analysis on the 12 tumor samples profiled on all three
array platforms using these 54 genes clearly separated the
two subtypes of breast tumors (Figure 3C).
Real-time PCR validation using TaqMan® Gene Expression 
Assays
To further validate these prognostic markers, we selected
altogether 85 genes (the 54 minimal set of predictor genes
plus an additional 14 top-ranking predictor genes from
the PAM analysis, 10 previously identified markers (from
the intrinsic gene list) and 7 selected G-protein coupled
receptors (GPCRs) and secreted proteins) and performed
real-time PCR using TaqMan® Gene Expression Assays (see
Additional file 5). Profile correlation analysis showed that
the expression profiles across the 20 tumor samples deter-
mined by each array platform and by TaqMan® assays are
highly correlated (Figure 5) (median correlation coeffi-
cient R > 0.9, the rate of good correlation (Pearson corre-
lation coefficient, R > 0.8) varied from 81–88% for the
three array platforms (Table 2). Hierarchical clustering
analysis not only demonstrated excellent separation of the
luminal A and basal-like subtypes, but that the same
tumor sample analyzed by three microarray platforms and
the TaqMan® assays were clustered together by tumor sam-
ple rather than by method (Figure 6).
Discussion
Analyses of gene expression patterns from thousands of
genes using DNA microarrays have demonstrated great
diversity among tumors arising in the same organ and
with apparently similar histopathology. This has raised
hopes that classification schemes based on molecular pro-
filing may better capture the complex behavior of tumors
and lead to improved prognostication and tailor-made
therapeutic strategies. We were the first to identify that
specific subclasses of breast cancer, based on gene expres-
sion profiling, were distinct biological entities and associ-
ated with significant differences in outcome for patients
with locally advanced breast cancer [4]. Subsequently, this
has been validated both by us and other groups in differ-
ent types of breast cancer patient cohorts [3,9-13]. Here,
we could confirm the existence of the molecular subtypes
of breast tumors also in early breast cancer (T1/T2) using
three different microarray platforms. Due to the small
sample size reported here, only the luminal A and basal-
like groups could be robustly identified, although the
other less represented subtypes could also be recognized.
These two subtypes are easily distinguishable in several
tumor data sets and their expression profiles seem to be
anti-correlated, as also has been shown for breast cancer
cell lines [24], but the cellular pathways affected are not
known in detail. We show here that the differences in gene
expression patterns between the two main subtypes reflect
levels of activation of distinct signaling pathways. These
Table 2: Pearson correlation between gene expression profiles determined by TaqMan real-time PCR and three DNA microarray 
platforms
Pearson Correction with TaqMan Assay Applied Biosystems Stanford cDNA Array Agilent
Good (cor.coeff. > 0.8) 75 (88%) 69 (81%) 73 (86%)
Consistent (0 < cor.coeff. < 0.8) 8 (9%) 15 (18%) 9 (11%)
Anti-Correlation (cor.coeff. < 0) 2 (2%) 1(1%) 3 (4%)
Median 0.91 0.90 0.91Page 8 of 15
(page number not for citation purposes)
BMC Genomics 2006, 7:127 http://www.biomedcentral.com/1471-2164/7/127changes might have been pre-programmed already at a
relatively early stage in the progression of the cancer and
hence, imply that the fate of the tumor is already set. This
is in accordance with previous reports on breast cancer
[3,9,10,25-27]. Other groups have analyzed gene expres-
sion in DCIS (ductal carcinoma in situ) for comparison
with invasive carcinomas and highlighted transcripts that
may be important for transformation and invasion
[13,28,29]. Extensive studies of DCIS and other pre-inva-
sive stages of tumors will further enlighten this hypothesis
and substantiate the value of gene expression-based clas-
sification in prognosis of breast cancer at an early stage.
Specifically in this study, a more in-depth molecular char-
acterization of these phenotypes of breast cancer was car-
ried out and provided new insights into the biology of the
disease at the molecular level. The distinct and character-
istic molecular mechanisms revealed by the protein classi-
fication and biological pathway analysis, provided further
evidence that these molecular subtypes represent biologi-
cally distinct disease entities and may require different
Validation of potential prognostic markers by Taqman® assay-based real-time PCRFigure 5
Validation of potential prognostic markers by Taqman® assay-based real-time PCR. 85 marker genes including the 
minimal set of 54 genes identified to best distinguish the luminal A and the basal-like subtypes were validated by TaqMan® Gene 
Expression assays. Profile correlation analysis showed the expression profile across the 20 tumor samples determined by the 
three microarray platforms and by TaqMan® Gene Expression assays are highly correlated with median correlation coefficient 
R > 0.9 and a rate of good correlation (R > 0.8) of 81–88%.
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BMC Genomics 2006, 7:127 http://www.biomedcentral.com/1471-2164/7/127therapeutic strategies. For example, our results indicated
that the luminal A subtype showed coordinated activation
of genes involved in steroid/estrogen signaling and fatty
acid metabolism. Fatty acid synthase (FAS)-dependent
endogenous fatty acid synthetic activity has been found to
be abnormally elevated in a subset of aggressive breast car-
cinomas [30], in particular ERBB2-overexpressing tumors
[31], whereas here, high expression of many genes
involved in fatty acid/lipid metabolism and degradation
were coupled to the luminal A phenotype, know to be
associated with a relatively good prognosis [10]. Although
no correlation between fatty acid metabolism and estro-
gen and progesterone receptor expression status of tumors
has been documented in cancer, our results may indicate
some level of cross-talk between fatty acid metabolism
and steroid signaling that may have effects on apoptosis
and cell proliferation and possibly hormonal treatment in
this subtype of breast cancer. Indeed, it has been specu-
lated that some lipids may modulate steroid metabolism
[32].
Such molecular profiling of clinically relevant subtypes of
breast tumors provide opportunities for identification of
novel targets that can be exploited for targeted therapeu-
tics of the disease. Among the 1210 genes most differen-
tially expressed between luminal A and basal-like tumors,
145 are secreted proteins based on the prediction method-
ology published in a recent paper [33]. A variety of bio-
molecules are secreted proteins such as cytokines,
chemokines, hormones and digestive enzymes that play
pivotal biological regulatory roles and are very important
sources for protein therapeutics. We also identified five G
Hierarchical clustering analysis of expression data from the TaqMan® assays and the three microarray platforms across the 85 marker genesFigure 6
Hierarchical clustering analysis of expression data from the TaqMan® assays and the three microarray plat-
forms across the 85 marker genes. The same tumor sample analyzed by the three microarray platforms and the TaqMan® 
Gene Expression assays were clustered together except for one sample (MicMa185). For the Applied Biosystems microarrays, 
the mean expression values of the two microarray replicates were presented. The transformed z-scores were represented 
using a red-black-green color scale as shown in the key (green: below mean; black: equal to mean; red: above mean).
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ture genes, a gene family well established as small mole-
cule drug targets.
Although we analyzed only 20 tumor biopsies, data were
collected using three different microarray platforms; a
two-color fluorescent-based cDNA microarray, a 60-mer
oligo microarray using two-color fluorescence detection
and a 60-mer oligo microarray using chemiluminescence
detection. Of 16,611 common genes among these three
platforms, 1019, 1054 and 1164 genes, respectively, were
identified to be differentially expressed between luminal
A and basal-like tumors. Of these, 319 genes were com-
mon to all three technologies, which correspond to an
overall consistency of 30%. These numbers could prove to
be even higher if a more accurate probe match by
sequence rather than gene identifiers would be per-
formed, as has recently been shown [34]. A few studies
have recently been published that aimed to compare vari-
ability and consistency between microarray platforms and
with different results [35-37]. Our study shows that
although there is variability between the platforms, the
gene expression profiles emerging from using all three
technologies are highly correlated to the biological varia-
tion in the data and the same tumor subtype pattern was
identified with all three methods.
The minimal set of 54 genes that best characterized lumi-
nal A and basal-like subtypes was identified based on dif-
ferential expressed genes on all three platforms and
validated by using TaqMan® assays. Convincingly, cluster-
ing of expression data from all four methods grouped the
experiments together by tumor sample of origin and not
by platform. Hence, these genes provide a robust set of
potential prognostic molecular markers, but which covers
only the two main subtypes. More thorough characteriza-
tion on significantly larger sample sizes is needed to pro-
vide prognostic predictor sets for all subtypes.
Conclusion
We have validated and characterized the two main previ-
ously defined clinically relevant subtypes, luminal A and
basal-like, in early stage breast carcinomas, using three
different DNA microarray platforms. Signature gene pro-
files characterizing these two subtypes revealed that dis-
tinct molecular mechanisms might have been pre-
programmed at an earlier stage in different subtypes of the
disease. Our results provide further evidence that these
breast tumor subtypes represent biologically distinct dis-
ease entities and may require different therapeutic strate-
gies. Finally, validated by the gene expression platforms
and TaqMan® assay-based real time PCR, the set of 54 pre-
dictor genes identified in this study defines a set of highly-
validated and potential prognostic molecular markers for
these subtypes of breast cancer.
Methods
Tumor samples and RNA preparation
Tissue samples from a pilot set of 20 breast carcinomas, a
small subset of a larger series of 920 unselected early-stage
breast cancer patients, for which informed, written con-
sent was obtained by the Regional Ethical Committee
[38], were analyzed in this study. Samples were fresh fro-
zen immediately after surgery and stored at -80°C. All
specimens analyzed contained more than 40% tumor
cells (of the total number of cells counted). The majority
of tumors were invasive ductal carcinomas, T1/T2, N0/N1
and histological grade 2 and 3 (Additional file 6). Total
RNA was isolated by phenol-chloroform extraction (TRI-
zol reagent, Invitrogen), the quality and integrity of the
total RNA was evaluated on the 2100 Bioanalyzer (Agilent
Technologies) and the concentration was measured using
a NanoDrop spectrophotometer (NanoDrop Technolo-
gies).
Applied Biosystems expression array analysis
The Applied Biosystems Human Genome Survey Microar-
ray (P/N 4337467) contains 31,700 60-mer oligonucle-
otide probes representing 27,868 individual human
genes. Digoxigenin-UTP labeled cRNA was generated and
amplified from 2 µg of total RNA from each sample using
Applied Biosystems Chemiluminescent RT-IVT Labeling
Kit v 1.0 (P/N 4340472) according to the manufacturer's
protocol (P/N 4339629). Array hybridization was per-
formed for 16 hrs at 55 °C. Chemiluminescence detec-
tion, image acquisition and analysis were performed
using Applied Biosystems Chemiluminescence Detection
Kit (P/N 4342142) and Applied Biosystems 1700 Chemi-
luminescent Microarray Analyzer (P/N 4338036) follow-
ing the manufacturer's protocol (P/N 4339629). Images
were auto-gridded and the chemiluminescent signals were
quantified, corrected for background, and finally, spot-
and spatially-normalized using the Applied Biosystems
1700 Chemiluminescent Microarray Analyzer software v
1.1 (P/N 4336391). A total of 40 microarrays were used
for the analysis: Two process replicates (independent labe-
ling and independent hybridization process) were gener-
ated for each of 10 samples, and two technical replicates
(the same pool of labeled cRNA and then split into two
independent array hybridizations) were generated for the
remaining 10 samples. For inter-array normalization, we
applied global median normalization across all microar-
rays to achieve the same median signal intensities for each
array.
Stanford human cDNA microarray analysis
The same RNA samples were also analyzed using Stanford
Human cDNA microarrays, which contain 42,000 fea-
tures representing 24,271 unique cluster IDs (UniGene
Build Number 173), manufactured by the Stanford Func-
tional Genomic Facility [39]. Amplification was per-Page 11 of 15
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[40] using the MessageAmp amplification kit (Ambion)
and labeling of 3 µg total RNA per sample was carried out
as previously described using incorporation of Cy5 for
tumor RNA and Cy3 for reference RNA (Stratagene UHR)
[41]. Hybridization at 65°C was performed overnight, the
hybridized arrays were scanned on an Agilent DNA micro-
array scanner and images analyzed by GenePix Pro v 4.1.
The Limma package (R/Bioconductor) [42] was used to
perform within array normalization (print-tip loess nor-
malization) and between array normalization (median of
absolute deviation normalization).
Agilent whole human genome microarray analysis
The Agilent Whole Human Genome Oligo Microarray
contains 44,000 60-mer oligonucleotide probes repre-
senting 41,000 unique genes and transcripts [43]. Ampli-
fication and labeling of 500 ng of total RNA was
performed according to the manufacturer's protocol using
Cy5 for tumor RNA and Cy3 for the reference RNA (Strat-
agene UHR). Hybridization was performed for 16 hrs at
50°C and arrays were scanned on an Agilent DNA micro-
array scanner. Images were analyzed and data were
extracted using Agilent Feature Extraction Software
A.7.5.1. Lowess normalization was performed for within
array normalization between the two channels and a lin-
ear scaling (geometric mean of each channel signal is set
to a value of 1000) was performed for between array nor-
malization.
Cross-mapping between microarray platforms
All target transcripts of Applied Biosystems Human
Genome Survey Microarray were identified by mapping
the 60-mer probe sequences to all transcript sequences
from both Celera and public databases including Celera
hCT, RefSeq NMs, GenBank mRNAs, MGCs, dbESTs, Gen-
Bank CDS, Ensembl cDNA; all target transcripts repre-
sented on the Stanford cDNA microarray and the Agilent
Whole Human Genome Oligo Microarray were identified
by the targeted GenBank accession numbers representing
the corresponding probes as specified by each manufac-
turer. All transcript sequences were then mapped to the
Celera-assembled human genome (Build R27) and a tran-
script-to-gene-clustering was performed so that each tran-
script could be traced to a gene (removing redundancy)
(Xiao C. et al, manuscript in preparation). The common
target transcrips between Applied Biosystems Human
Genome Survey Microarray and the Stanford Human
cDNA microarray (17,732 genes) and between the
Applied Biosystems Human Genome Survey Microarray
and the Agilent Whole Human Genome Oligo Microarray
(22,507 genes) respectively, were identified based on their
common cluster membership, respectively. Intersect
genes (16,611 genes; see Additional file 3) of these two
gene lists were used as the common genes among all three
platforms.
TaqMan® assay-based real-time PCR
mRNA expression of 85 target genes and 4 endogenous
control genes was measured in each of the 20 biopsy spec-
imens by real-time PCR using TaqMan® Gene Expression
Assays and the ABI PRISM® 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, CA). Four repli-
cates were run for each gene for each sample in a 384-well
format plate. The probes contain a 6-carboxy-fluorescein
phosphoramidite (FAM™ dye) label at the 5' end of the
gene and a minor groove binder and non-fluorescent
quencher at the 3' end and are designed to hybridize
across exon junctions. ~ 4 µg of total RNA from each
tumor sample was used to generate cDNA using the ABI
High Capacity cDNA Archiving Kit (Applied Biosystems,
Foster City, CA) and the real-time PCR reactions were car-
ried out following the manufacturer's protocol. TaqMan®
Gene Expression Assay IDs are listed in Additional file 6.
Among the four measured endogenous control genes
(RPS18/PPIA (Alias: cyclophilin A)/GAPDH/PGK1) we
chose PPIA for normalization across different genes based
on the fact that this gene showed the most relatively con-
stant expression in different breast carcinomas (see Addi-
tional file 7).
Statistical analysis
Statistical analyses were performed with the software
packages MATLAB® (Mathworks, Natick, MA), R/Biocon-
ductor [42] GeneSpring (Agilent Technologies, CA) and
Spotfire Functional Genomic (Spotfire, Göteborg, Swe-
den).
Centroid correlation analysis
An "intrinsic" gene list consisting of 534 genes repre-
sented by 552 clones, was previously selected based on
their low variation in expression in successive samples
from the same patient's tumor and at the same time, high
degree of variation among tumors from different patients
[10]. These intrinsic genes have been used to define five
subtypes of breast tumors and their core expression cen-
troids (i.e., average expression profile of the 534 intrinsic
genes) in a data set of 122 breast tissue samples, most of
which were locally advanced breast tumors. 526 of the
intrinsic genes were mapped to the corresponding genes
represented on the Applied Biosystems Human Genome
Survey Microarray and 510 were mapped among all three
microarray platforms used in this study. Using these
mapped genes, we computed the Pearson's correlation
coefficient of each sample from this study to each of the
five centroids and assigned each sample to the subtype
with which it showed the highest correlation.Page 12 of 15
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Average-linkage hierarchical clustering analysis and visu-
alization was performed using the Cluster and TreeViev
programs [44]. When multiple platform data were ana-
lyzed together, each data set was first normalized between
arrays and between genes independently, and then com-
bined for clustering analysis. For the single-color Applied
Biosystems microarray platform, gene expression signals
were first normalized between arrays to the same median
expression level in log2 space, and then normalized by
median expression level or by z-score transformation
across all samples for each gene. For the two-color array
systems (Stanford cDNA microarrays and Agilent oligo
arrays), normalization within and between arrays were
performed using the log2 ratio of the sample vs. the refer-
ence as described earlier, and then normalized by median
expression ratio or by z-score transformation across all
samples for each gene. For TaqMan® assay-based real-time
PCR, -∆Ct = Ct_endogenous control – Ct_gene was calcu-
lated as an equivalent of normalized relative gene expres-
sion level, and then z-score-transformed across all
samples for each gene. The z-score was determined as
number of standard deviations of the level of expression
of each gene in each sample away from the mean level of
expression of that gene across all the samples within the
data set of the given platform.
PAM
Class prediction was performed by using prediction anal-
ysis of microarrays (PAM), a statistical package [45] that
applies nearest shrunken centroid analysis and cross-vali-
dation to determine a minimal set of predictor genes that
achieve optimal prediction accuracy for sample classifica-
tion [46].
Differential expression analysis
Welch-ANOVA analysis coupled with Benjamini and
Hochberg False Discovery Rate multiple testing correc-
tions were performed using GeneSpring software package
to identify the most diferentially expressed genes between
the luminal A and basal-like subtypes.
PANTHER™ protein classification system analysis
Similar to Gene Ontology™ (GO), PANTHER™ (Protein
ANalysis THrough Evolutionary Reationships) Protein
Classification System (Applied Biosystems, Foster City,
CA) [47] classifies proteins in families/sub-families,
molecular functions, biological processes and biological
pathways. Compared to GO, the PANTHER™ Protein
Classification System provides a more simplified ontol-
ogy (vocabulary) of protein function and classifies 25%
more proteins than GO [48]. Protein classification over-
represented by "signature" genes of the luminal A and the
basal subtype were identified and the statistical signifi-
cance of the over-representation was quantified by a ran-
dom overlapping p value using the binomial test with all
the genes represented by the Applied Biosystems Human
Genome Survey Microarray as the reference list [49].
Pathway analysis
Pathway analysis was performed using PathArt™ (Jubilant
Biosys Ltd., Mahalakshmipuram, Bangalore). PathArt is a
curated database of biomolecular interactions with more
than 1400 regulatory and signaling pathways. Compared
to a few publicly available pathway databases (i.e. Gen-
Mapp [50], KEGG [51]), which tend to be heavily
enriched in metabolic pathways, the PathArt database
emphasizes more on disease specific networks and regula-
tory and signaling pathways. The statistical significance of
the over-representation of the given pathway within each
"signature" gene list was quantified as a similarity p-value
(likelihood of a random overlapping) using script SG3b-
1 (BioScripts 2.1, GeneSpring software) based on Fisher's
Exact Test.
Profile correlation between microarray and TaqMan® assay-based 
real-time PCR data
Data sets from each microarray platform and TaqMan®
Gene Expression assays were normalized sample-wise and
gene-wise (z-score transformation) as described above.
Pearson's correlation coefficient (R) was calculated
between the expression profile for each of the 85 valida-
tion target genes across the 20 tumor samples determined
by each microarray platform and the expression profile
determined by TaqMan® Gene Expression assays.
GEO accession
The data from three microarray platforms and the Taq-
Man gene expression assays have been deposited in Gene
Expression Omnibus (GEO 3155) [52].
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